The analysis simulated hypothetical wastewater detection curves using poliovirus case counts from Belgium between 1940 to 1965, incorporating polio seasonality and faecal shedding patterns. A summer onset assumption was applied, and the final curves were adjusted using local climate data for European cities with poliovirus detections to determine the start of the summer season.
Real-world detected wastewater poliovirus load for all 36 European cities with detections fell within the intervals predicted by the model. “This gives us the indication that polio could have been imported at a low level of circulation in those areas”, said Dr Hansford. “What we saw with the sudden onset of wastewater detections was a natural seasonal peak occurring as transmission increased in those areas.”
Overall, NIE-ZAS-1 wastewater detections in late 2024 were consistent with silent, endemic circulation characterised by seasonal amplification, rather than with multiple simultaneous importations. “My conclusion is that when we talk about vaccines, let’s not forget polio”, said Dr Hansford. “It remains very important, and it is something we need to remember.”
- Detections of poliovirus in sewage samples require enhanced routine and catch-up vaccination and increased surveillance. Available from: https://www.ecdc.europa.eu/en/news-events/detections-poliovirus-sewage-samples-require-enhanced-vaccination-surveillance (accessed 15 September 2025)
- Rowland T, et al. Euro Surveill. 2025;30(16):2500025.
- Hansford K, et al. Seasonal amplification of poliovirus detection in Europe: An evidence may suggest silent circulation of the NIE-ZAS-1 cVDPV2 variant. 6th ESCMID Conference on Vaccines, 10–13 September 2025, Lisbon, Portugal.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation Next Article
V116 shows promise for adults at risk of pneumococcal disease »
« Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation Next Article
V116 shows promise for adults at risk of pneumococcal disease »
Related Articles
September 16, 2025
European pregnant women show openness to maternal RSV vaccination
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
